

Hundreds of variants clustered in genomic loci and biological pathways affect human height

A full list of authors and their affiliations appears at the end of the paper.

Most common human traits and diseases have a polygenic pattern of inheritance: DNA sequence variants at many genetic loci influence the phenotype. Genome-wide association (GWA) studies have identified more than 600 variants associated with human traits¹, but these typically explain small fractions of phenotypic variation, raising questions about the use of further studies. Here, using 183,727 individuals, we show that hundreds of genetic variants, in at least 180 loci, influence adult height, a highly heritable and classic polygenic trait^{2,3}. The large number of loci reveals patterns with important implications for genetic studies of common human diseases and traits. First, the 180 loci are not random, but instead are enriched for genes that are connected in biological pathways ($P = 0.016$) and that underlie skeletal growth defects ($P < 0.001$). Second, the likely causal gene is often located near the most strongly associated variant: in 13 of 21 loci containing a known skeletal growth gene, that gene was closest to the associated variant. Third, at least 19 loci have multiple independently associated variants, suggesting that allelic heterogeneity is a frequent feature of polygenic traits, that comprehensive explorations of already-discovered loci should discover additional variants and that an appreciable fraction of associated loci may have been identified. Fourth, associated variants are enriched for likely functional effects on genes, being over-represented among variants that alter amino-acid structure of proteins and expression levels of nearby genes. Our data explain approximately 10% of the phenotypic variation in height, and we estimate that unidentified common variants of similar effect sizes would increase this figure to approximately 16% of phenotypic variation (approximately 20% of heritable variation). Although additional approaches are needed to dissect the genetic architecture of polygenic human traits fully, our findings indicate that GWA studies can identify large numbers of loci that implicate biologically relevant genes and pathways.

In stage 1 of our study, we performed a meta-analysis of GWA data from 46 studies, comprising 133,653 individuals of recent European ancestry, to identify common genetic variation associated with adult height. To enable meta-analysis of studies across different genotyping platforms, we performed imputation of 2,834,208 single nucleotide polymorphisms (SNPs) present in the HapMap Phase 2 European-American reference panel⁴. After applying quality control filters, each individual study tested the association of adult height with each SNP using an additive model (Supplementary Methods). The individual study statistics were corrected using the genomic control method^{5,6} and then combined in a fixed effects based meta-analysis. We then applied a second genomic control correction on the meta-analysis statistics, although this approach may be overly conservative when there are many real signals of association (Supplementary Methods). We detected 207 loci (defined as 1 megabase (Mb) on either side of the most strongly associated SNP) as potentially associated with adult height ($P < 5 \times 10^{-6}$).

To identify loci robustly associated with adult height, we took forward at least one SNP (Supplementary Methods) from each of the 207 loci reaching $P < 5 \times 10^{-6}$ into an additional 50,074 samples (stage 2) that became available after completion of our initial meta-analysis. In

the joint analysis of our stage 1 and stage 2 studies, SNPs representing 180 loci reached genome-wide significance ($P < 5 \times 10^{-8}$; Supplementary Figs 1 and 2 and Supplementary Table 1). Additional tests, including genotyping of a randomly-selected subset of 33 SNPs in an independent sample of individuals from the fifth to tenth and ninetieth to ninety-fifth percentiles of the height distribution ($n = 3,190$)⁷, provided further validation of our results, with all but two SNPs showing consistent direction of effect (sign test $P < 7 \times 10^{-8}$) (Supplementary Methods and Supplementary Table 2).

Genome-wide association studies can be susceptible to false positive associations from population stratification⁷. We therefore performed a family-based analysis, which is immune to population stratification, in 7,336 individuals from two cohorts with pedigree information. Alleles representing 150 of the 180 genome-wide significant loci were associated in the expected direction (sign test $P < 6 \times 10^{-20}$; Supplementary Table 3). The estimated effects on height were essentially identical in the overall meta-analysis and the family-based sample. Together with several other lines of evidence (Supplementary Methods), this indicates that stratification is not substantially inflating the test statistics in our meta-analysis.

Common genetic variants have typically explained only a small proportion of the heritable component of phenotypic variation⁸. This is particularly true for height, where more than 80% of the variation within a given population is estimated to be attributable to additive genetic factors⁹, but over 40 previously published variants explain less than 5% of the variance¹⁰⁻¹⁷. One possible explanation is that many common variants of small effects contribute to phenotypic variation, and current GWA studies remain underpowered to detect most common variants. Using five studies not included in stage 1, we found that the 180 associated SNPs explained on average 10.5% (range 7.9-11.2%) of the variance in adult height (Supplementary Methods). Including SNPs associated with height at lower significance levels¹⁸ ($0.05 > P > 5 \times 10^{-8}$) increased the variance explained to 13.3% (range 9.7-16.8%) (Fig. 1a). In addition, we found no evidence that non-additive effects including gene-gene interaction would increase the proportion of the phenotypic variance explained (Supplementary Methods and Supplementary Tables 5 and 6).

As a separate approach, we used a recently developed method¹⁹ to estimate the total number of independent height-associated variants with effect sizes similar to the ones identified. We obtained this estimate using the distribution of effect sizes observed in stage 2 and the power to detect an association in stage 1, given these effect sizes (Supplementary Methods). The cumulative distribution of height loci, including those we identified and others as yet undetected, is shown in Fig. 1b. We estimate that there are 697 loci (95% confidence interval: 483-1040) with effects equal or greater than those identified, which together would explain approximately 15.7% of the phenotypic variation in height or 19.6% (95% confidence interval: 16.2-25.6) of height heritability (Supplementary Table 4). We estimated that a sample size of 500,000 would detect 99.6% of these loci at $P < 5 \times 10^{-8}$. This figure does not account for variants that have effect sizes smaller than those observed in the current study and, therefore, underestimates the contribution of undiscovered common genetic variants to phenotypic variation.




Figure 1 | Phenotypic variance explained by common variants. **a**, Variance explained is higher when SNPs not reaching genome-wide significance are included in the prediction model. The y axis represents the proportion of variance explained at different P-value thresholds from stage 1. Results are given for five studies that were not part of stage 1. The proportion of variation explained by the 180 SNPs is shown in the column to the right of the graph. **b**, Cumulative number of susceptibility loci expected to be discovered, including already identified loci and as yet undetected loci. The projections are based on loci that achieved a significance level of $P < 5 \times 10^{-8}$ in the initial scan and the distribution of their effect sizes in stage 2. The dotted red line corresponds to expected phenotypic variance explained by the 110 loci that reached genome-wide significance in stage 1, were replicated in stage 2 and had at least 1% power.

A further possible source of missing heritability is allelic heterogeneity: the presence of multiple, independent variants influencing a trait at the same locus. We performed genome-wide conditional analyses in a subset of stage 1 studies, including a total of 106,336 individuals. Each study repeated the primary GWA analysis but additionally adjusted for SNPs representing the 180 loci associated at $P < 5 \times 10^{-6}$ (Supplementary Methods). We then meta-analysed these studies in the same way as for the primary GWA study meta-analysis. Nineteen SNPs within the 180 loci were associated with height at $P < 3.3 \times 10^{-7}$ (a Bonferroni-corrected significance threshold calculated from the approximately 15% of the genome covered by the conditioned 2 Mb loci; Table 1, Fig. 2, Supplementary Methods and Supplementary Figs 1 and 3). The distances of the second signals to the lead SNPs suggested that both are likely to be affecting the same gene, rather than being coincidentally in close proximity. At 17 of 17 loci (excluding two contiguous loci in the *HMGAI* region), the second signal occurred within 500 kilobases (kb), rather than between 500 kb and 1 Mb, of this lead SNP (binomial test $P = 2 \times 10^{-5}$). Further analyses of allelic heterogeneity may identify additional variants that increase the proportion of variance explained. For example, within the 180 2-Mb loci, a total of 45 independent SNPs reached $P < 1 \times 10^{-5}$ when we would expect less than 2 by chance.

Although GWA studies have identified many variants robustly associated with common human diseases and traits, the biological significance of these variants, and the genes on which they act, is often unclear. We first tested the overlap between the 180 height-associated variants and two types of putatively functional variants, non-synonymous (ns) SNPs and cis-expression quantitative trait loci (cis-eQTLs, variants strongly associated with expression of nearby genes). Height variants were 2.4-fold more likely to overlap with cis-eQTLs in lymphocytes than expected by chance (47 variants: $P = 4.7 \times 10^{-11}$) (Supplementary Table 7) and 1.7-fold more likely to be closely correlated ($r^2 \geq 0.8$ in the HapMap CEU sample) with nsSNPs (24 variants, $P = 0.004$) (Supplementary Methods and Supplementary Table 8). Although the presence of a correlated cis-eQTL or nsSNP at an individual locus does not establish the causality of any particular variant, this enrichment shows that common functional variants contribute to the causal variants at height-associated loci. We also noted five loci where the height associated variant was strongly correlated ($r^2 > 0.8$) with variants associated with other traits and diseases ($P < 5 \times 10^{-8}$), including bone mineral density, rheumatoid arthritis, type 1 diabetes, psoriasis and obesity, suggesting that these variants have pleiotropic effects on human phenotypes (Supplementary Methods and Supplementary Table 9).

Table 1 | Secondary signals at associated loci after conditional analysis

Second signal SNP	Conditioned SNP	Chromosome	Second signal SNP position	Distance of conditioned SNP from index SNP (base pairs)	HapMap* r^2	Second signal P value after conditioning	Second signal P value pre-conditioning	Gene†
rs2280470	rs16942341	15	87,196,630	6,721	0.009	1×10^{-14}	1×10^{-15}	ACAN
rs10859563	rs11107116	12	92,644,470	141,835	0.003	3×10^{-12}	8×10^{-10}	SOCS2
rs750460	rs5742915	15	72,028,559	95,127	0.004	4×10^{-12}	7×10^{-8}	PML
rs6938239	rs2780226‡	6	34,791,613	484,583	0.019	6×10^{-12}	9×10^{-14}	HMGAI
rs7652177	rs572169	3	173,451,771	196,650	0.006	7×10^{-11}	1×10^{-11}	GHSR
rs7916441	rs2145998	10	80,595,583	196,119	0.112	6×10^{-10}	3×10^{-7}	PP1F
rs3792752	rs1173727	5	32,804,391	61,887	0.020	7×10^{-10}	4×10^{-8}	NPR3
rs10958476	rs7460090	8	57,258,362	98,355	0.020	1×10^{-9}	5×10^{-13}	SDR16C5
rs2353398	rs7689420	4	145,742,208	45,594	0.022	2×10^{-9}	1×10^{-10}	HHIP
rs2724475	rs6449353	4	17,555,530	87,056	0.098	2×10^{-9}	8×10^{-16}	LCORL
rs2070776	rs2665838	17	59,361,230	41,033	0.150	9×10^{-9}	1×10^{-14}	GH region
rs1401796	rs227724	17	52,194,758	60,942	0.005	2×10^{-8}	7×10^{-7}	NOG
rs4711336	rs2780226‡	6	33,767,024	540,046	0.111	3×10^{-8}	5×10^{-8}	HMGAI
rs6892884	rs12153391	5	170,948,228	187,815	0.000	4×10^{-8}	2×10^{-5}	FBXW11
rs1367226	rs3791675	2	55,943,044	21,769	0.204	4×10^{-8}	0.1245	EFEMP1
rs2421992	rs17346452	1	170,507,874	187,964	0.019	5×10^{-8}	1×10^{-5}	DNM3
rs225694	rs7763064	6	142,568,835	270,147	0.001	1×10^{-7}	2×10^{-6}	GPR126
rs10187066	rs12470505	2	219,223,003	393,610	0.022	2×10^{-7}	5×10^{-8}	IHH
rs879882	rs2256183	6	31,247,431	241,077	0.016	2×10^{-7}	8×10^{-8}	MICA

* HapMap CEU phase II release 23. † Nearest gene unless there is a known skeletal growth disorder gene in the locus. Positions are based on National Center for Biotechnology Information build 36. ‡ Nearest conditioned SNP where second signal occurs within 1 Mb of two conditioned SNPs.




Figure 2 | Example of a locus with a secondary signal before (a) and after (b) conditioning. The plot is centred on the conditioned SNP (purple diamond) at the locus. The values of r^2 are based on the CEU HapMap II samples. The blue line and right-hand y axis represent CEU HapMap II recombination rates. The figure was created using LocusZoom (<http://csg.sph.umich.edu/locuszoom/>).

We next addressed the extent to which height variants cluster near biologically relevant genes; specifically, genes mutated in human syndromes characterized by abnormal skeletal growth. We limited this analysis to the 652 genes occurring within the recombination hotspot-bounded regions surrounding each of the 180 index SNPs. We showed that the 180 loci associated with variation in normal height contained 21 of 241 genes (8.7%) found to underlie such syndromes (Supplementary Fig. 1 and Supplementary Table 10), compared with a median of 8 (range 1–19) genes identified in 1,000 matched control sets of regions ($P < 0.001$: 0 observations of 21 or more skeletal growth genes among 1,000 sets of matched SNPs). In 13 of these 21 loci the closest gene to the most associated height SNP in the region is the growth disorder gene, and in nine of these cases the most strongly associated height SNP is located within the growth disorder gene itself (Supplementary Methods and Supplementary Table 11). These results suggest that GWA studies may provide more clues about the identity of the functional genes at each locus than previously suspected.

We also investigated whether significant and relevant biological connections exist between the genes within the 180 loci, using two different computational approaches. We used the GRAIL text-mining algorithm to search for connectivity between genes near the associated SNPs, based on existing literature²⁰. Of the 180 loci, 42 contained genes that were connected by existing literature to genes in the other associated loci (the pair of connected genes appear in articles that share scientific terms more often than expected at $P < 0.01$). For comparison, when we used GRAIL to score 1,000 sets of 180 SNPs not associated with height (but matched for number of nearby genes, gene proximity and allele frequency), we only observed 16 sets with 42 or more loci with a connectivity $P < 0.01$, thus providing strong statistical evidence that the height loci are functionally related ($P = 0.016$) (Fig. 3a). For the 42 regions with GRAIL connectivity $P < 0.01$, the implicated genes and SNPs are highlighted in Fig. 3b. The most strongly connected genes include those in the Hedgehog, TGF- β and growth hormone pathways.

As a second approach to find biological connections, we applied a novel implementation of gene set enrichment analysis (meta-analysis gene-set enrichment of variant associations, MAGENTA²¹) to perform pathway analysis (Supplementary Methods). This analysis revealed 17 different biological pathways and 14 molecular functions nominally enriched ($P < 0.05$) for associated genes, many of which lie within the validated height loci. These gene-sets include previously reported^{11,13} (for example, Hedgehog signalling) and novel (for example, TGF- β signalling, histones, and growth and development-related) pathways and molecular functions (Supplementary Table 12). Several SNPs near genes in these pathways narrowly missed genome-wide significance, suggesting that these pathways likely contain additional associated variants. These results provide complementary evidence for some of the genes and pathways highlighted in the GRAIL analysis. For instance, genes such as *TGFB2* and *LTBP1-3* highlight a role for the TGF- β signalling pathway in regulating human height, consistent with the implication of this pathway in Marfan syndrome²².

Finally, to examine the evidence for the potential involvement of specific genes at individual loci, we aggregated evidence from our data (expression quantitative trait loci, proximity to the associated variant, pathway-based analyses), and human and mouse genetic databases (Supplementary Table 13). Of 32 genes with highly correlated ($r^2 > 0.8$) nsSNPs, several are newly identified strong candidates for playing a role in human growth. Some are in pathways enriched in our study (such as *ECM2*, implicated in extracellular matrix), whereas others have similar functions to known growth-related genes, including *FGFR4* (*FGFR3* underlies several classic skeletal dysplasias²³) and *STAT2* (*STAT5B* mutations cause growth defects in humans²⁴). Interestingly, *Fgfr4*^{-/-} *Fgfr3*^{-/-} mice show severe growth retardation not seen in either single mutant²⁵, suggesting that the *FGFR4* variant might modify *FGFR3*-mediated skeletal dysplasias. Other genes at associated loci, such as *NPPC* and *NPR3* (encoding the C-type natriuretic peptide and its receptor), influence skeletal growth in mice and will likely also influence human growth¹⁷. Many of the remaining 180 loci have no genes with obvious connections to growth biology, but at some our data provide modest supporting evidence for particular genes, including *C3orf63*, *PML*, *CCDC91*, *ZNF13*, *ID4*, *RYBP*, *SEPT2*, *ANKRD13B*, *FOLH1*, *LRRC37B*, *MFAP2*, *SLBP*, *SOCS5* and *ZBTB24* (Supplementary Table 13).

We have identified more than 100 novel loci that influence the classic polygenic trait of normal variation in human height, bringing the total to 180. Our results have potential general implications for genetic studies of complex traits. We show that loci identified by GWA studies highlight relevant genes: the 180 loci associated with height are non-randomly clustered within biologically relevant pathways and are enriched for genes that are involved in growth-related processes, that underlie syndromes of abnormal skeletal growth and that are directly relevant to growth-modulating therapies (*GHI*, *IGF1R*, *CYP19A1*, *ESR1*). The large number of loci with clearly relevant genes suggests that the remaining loci could provide potential clues to important and novel biology.

associations with measures of skeletal frame size. *PLoS Genet.* **5**, e1000445 (2009).

15. Gudbjartsson, D. F. *et al.* Many sequence variants affecting diversity of adult human height. *Nature Genet.* **40**, 609–615 (2008).
16. Johansson, A. *et al.* Common variants in the JAZF1 gene associated with height identified by linkage and genome-wide association analysis. *Hum. Mol. Genet.* **18**, 373–380 (2009).
17. Estrada, K. *et al.* A genome-wide association study of northwestern Europeans involves the C-type natriuretic peptide signaling pathway in the etiology of human height variation. *Hum. Mol. Genet.* **18**, 3516–3524 (2009).
18. Purcell, S. M. *et al.* Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748–752 (2009).
19. Park, J. H. *et al.* Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. *Nature Genet.* **42**, 570–575 (2010).
20. Raychaudhuri, S. *et al.* Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS Genet.* **5**, e1000534 (2009).
21. Segre, A. V. *et al.* Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet.* **6**, e1001058 (2010).
22. Neptune, E. R. *et al.* Dysregulation of TGF- β activation contributes to pathogenesis in Marfan syndrome. *Nature Genet.* **33**, 407–411 (2003).
23. Superti-Furga, A. & Unger, S. Nosology and classification of genetic skeletal disorders: 2006 revision. *Am. J. Med. Genet. A* **143**, 1–18 (2007).
24. Kofoed, E. M. *et al.* Growth hormone insensitivity associated with a STAT5b mutation. *N. Engl. J. Med.* **349**, 1139–1147 (2003).
25. Weinstein, M., Xu, X., Ohyama, K. & Deng, C. X. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. *Development* **125**, 3615–3623 (1998).
26. Goldstein, D. B. Common genetic variation and human traits. *N. Engl. J. Med.* **360**, 1696–1698 (2009).
27. Dickson, S. P., Wang, K., Krantz, I., Hakonarson, H. & Goldstein, D. B. Rare variants create synthetic genome-wide associations. *PLoS Biol.* **8**, e1000294 (2010).
28. Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human height. *Nature Genet.* **42**, 565–569 (2010).

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Acknowledgements Several participating studies are members of the CHARGE and ENGAGE consortia. We acknowledge funding from the following organizations: the Academy of Finland (104781, 117797, 120315, 121584, 126925, 129269, 129494, 129680, 213506); Affymetrix for genotyping services (N02-HL-6-4278); Agency for Science, Technology and Research of Singapore; ALF/LUA Gothenburg; Althingi (the Icelandic Parliament); Amgen; AstraZeneca AB; Australian National Health and Medical Research Council (241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688, 552485, 613672); Australian Research Council (DP0770096); Biocentrum Helsinki; Boston Obesity Nutrition Research Center (DK46200); British Diabetes Association; British Heart Foundation (PG/02/128); British Heart Foundation Centre for Research Excellence, Oxford; CamStrad; Cancer Research UK; Centre for Neurogenetics and Cognitive Research; Chief Scientist Office of the Scottish Government (CZB/4/279); Council of Health of the Academy of Finland; DIAB Core project of the German Network of Diabetes; Diabetes UK; Donald W. Reynolds Foundation; Emil and Vera Cornell Foundation; Erasmus MC; Estonian Government (SF0180142s08); European Commission (201413, ECOGENE:205419, BMRI:212111, OPENGNE:245536, ENGAGE:HEALTH-F4-2007-201413, EURO-DIA:LSHG-CT-2004-518153, EU/WLRT-2001-01254, HEALTH-F2-2008-ENGAGE, HEALTH-F4-2007-201550, LSH-2006-037593, LSHG-CT-2006-018947, LSHG-CT-2006-01947, Procardis:LSHM-CT-2007-037273, POLYGENE:LSHC-CT-2005, QLG1-CT-2000-01643, QLG2-CT-2002-01254, DG XII, Marie Curie Intra-European Fellowship); Eve Appeal; Finnish Ministry of Education; Finnish Diabetes Research Foundation; Finnish Diabetes Research Society; Finnish Foundation for Cardiovascular Research; Finnish Medical Society; Finska Läkaresällskapet; Folkhälsan Research Foundation; Fondation LeDucq; Foundation for Life and Health in Finland; Foundation for Strategic Research; GEN-AU-Programme 'GOLD'; Genetic Association Information Network; German Bundesministerium fuer Forschung und Technology (01 AK 803 A-H, 01 IG 07015 G); German Federal Ministry of Education and Research (01GS0831); German Ministry for Health, Welfare and Sports; German Ministry of Cultural Affairs; German Ministry of Education, Culture and Science; German National Genome Research Net (01GS0823, 01ZZ0103, 01ZZ0403, 01ZZ9603, 03ZIK012); German Research Council (KFO-152); GlaxoSmithKline; Göteborg Medical Society; Gyllenberg Foundation; Helmholtz Center Munich; Juvenile Diabetes Research Foundation International (U01 DK062418); Karolinska Institute; Knut and Alice Wallenberg Foundation; Lundberg Foundation; March of Dimes (6-FY-09-507); MC Health; Medical Research Council UK (G0000649, G0000934, G0500539, G0600331, G0601261, G9521010D, PrevMetSyn); Microarray Core Facility of the Interdisciplinary Centre for Clinical Research (B27); Mid-Atlantic Nutrition and Obesity Research Center of Maryland (P30 DK072488); Ministry of Health and Department of Educational Assistance (South Tyrol, Italy); Ministry of Science, Education and Sport of the Republic of Croatia (216-1080315-0302); Montreal Heart Institute Foundation; Närpes Health Care Foundation; National Cancer Institute; National Institute for Health Research Cambridge Biomedical Research Centre; National Institute for Health Research Oxford Biomedical Research Centre; National Institute for Health Research Comprehensive Biomedical Research Centre; National Institutes of Health (263-MA-410953, AA014041, AA07535, AA10248, AA13320, AA13321, AA13326, CA047988, CA49449, CA50385, CA65725, CA67262, CA87969, DA12854, DK062370, DK063491, DK072193, DK079466, DK080145,

DK58845, HG002651, HG005214, HG005581, HLO43851, HLO84729, HL69757, HL71981, K08-AR055688, K23-DK080145, K99-HL094535, M01-RR00425, MH084698, N01-AG12100, N01-AG12109, N01-HC15103, N01-HC25195, N01-HC35129, N01-HC45133, N01-HC55015, N01-HC55016, N01-HC55018, N01-HC55022, N01-HC55222, N01-HC75150, N01-HC85079, N01-HC85086, N01-HG65403, R01-AG031890, R01 CA104021, R01-DK068336, R01-DK073490, R01-DK075681, R01-DK075787, R01-HL086694, R01-HL087641, R01-HL087647, R01-HL087652, R01-HL087676, R01-HL087679, R01-HL087700, R01-HL088119, R01-HL59367, R01-MH059160, R01-MH59565, R01-MH59566, R01-MH59571, R01-MH59586, R01-MH59587, R01-MH59588, R01-MH60870, R01-MH60879, R01-MH61675, R01-MH63706, R01-MH67257, R01-MH79469, R01-MH81800, RL1-MH083268, T32-HG00040, U01-CA098233, U01-GM074518, U01-HG004399, U01-HG004402, U01-HL080295, U01-HL084756, U01-HL72515, U01-MH79469, U01-MH79470, U54-RR020278, UL1-RR025005, Z01-AG00675, Z01-AG007380, Z01-HG000024; contract HHSN268200625226C; ADA Mentor-Based Postdoctoral Fellowship; Pew Scholarship for the Biomedical Sciences; Netherlands Genomics Initiative/Netherlands Consortium for Healthy Aging (050-060-810); Netherlands Organisation for Scientific Research (investment number 175.010.2005.011, 911-03-012); Netherlands Organization for the Health Research and Development (10-000-1002); Netherlands Scientific Organization (904-61-090, 904-61-193, 480-04-004, 400-05-717, Center for Medical Systems Biology (NOW Genomics), SPI 56-464-1419); NIA Intramural Research Program; Nordic Center of Excellence in Disease Genetics; Novo Nordisk Foundation; Olqvist Foundation; Paavo Nurmi Foundation; Perklén Foundation; Petrus and Augusta Hedlunds Foundation; Queensland Institute of Medical Research; Radboud University Nijmegen Medical Centre; Research Institute for Diseases in the Elderly (014-93-015); Royal Swedish Academy of Science; Sahlgrenska Center for Cardiovascular and Metabolic Research (A305:188); Siemens Healthcare, Erlangen, Germany; Signe and Ane Gyllenberg Foundation; Sigrid Juselius Foundation; Social Insurance Institution of Finland; Social Ministry of the Federal State of Mecklenburg-West Pomerania; South Tyrolean Sparkasse Foundation; Stockholm County Council (560183); Support for Science Funding programme; Susan G. Komen Breast Cancer Foundation; Swedish Cancer Society; Swedish Cultural Foundation in Finland; Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation; Swedish Medical Research Council (K2007-66X-20270-01-3, 8691); Swedish National Cancer Institute; Swedish Research Council; Swedish Society of Medicine; Swiss National Science Foundation (33CSO-122661); Torsten and Ragnar Söderberg's Foundation; Vandervell Foundation; Västra Götaland Foundation; Wellcome Trust (072960, 075491, 079557, 079895, 083270, 068545/Z/02, 076113/B/04/Z, 076113/C/04/Z, 076113/C/04/Z, 077016/Z/05/Z, 081682/Z/06/Z, 084183/Z/07/Z, 085301/Z/08/Z, 086596/Z/08/Z, 091746/Z/10/Z; Wellcome Trust Research Career Development Fellowship); Western Australian Genetic Epidemiology Resource and the Western Australian DNA Bank (both National Health and Medical Research Council of Australia Enabling Facilities). A detailed list of acknowledgements by study is given in the Supplementary Information.

Author Contributions This work was done under the auspices of the Genetic Investigation of ANthropocentric Traits (GIANT) Consortium. Author contributions and roles are listed in the Supplementary Information.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of this article at www.nature.com/nature. Correspondence and requests for materials should be addressed to M.N.W. (michael.weedon@pms.ac.uk), G.R.A. (goncalo@umich.edu), K.S. (kstefans@decodis), T.M.F. (tim.frayling@pms.ac.uk) or J.N.H. (joelh@broadinstitute.org).

Hana Lango Allen^{1*}, Karol Estrada^{2,3,4*}, Guillaume Lettre^{5,6*}, Sonja I. Berndt^{7*}, Michael N. Weedon^{1*}, Fernando Rivadeneira^{2,3,4*}, Cristen J. Willer⁸, Anne U. Jackson⁸, Sailaja Vedantam^{9,10}, Soumya Raychaudhuri^{11,12}, Teresa Ferreira¹³, Andrew R. Wood¹, Robert J. Weyant⁸, Ayellet V. Segre^{11,14,15}, Elizabeth K. Speliotes^{10,16}, Eleanor Wheeler¹⁷, Nicole Soranzo^{17,18}, Ju-Hyun Park⁷, Jian Yang¹⁹, Daniel Gudbjartsson²⁰, Nancy L. Heard-Costa²¹, Joshua C. Randall¹³, Lu Q^{22,23}, Albert Vernon Smith^{24,25}, Reedik Mägi¹³, Tomi Pastinen^{26,27,28}, Liming Liang²⁹, Iris M. Heid^{30,31}, Jian'an Luan³², Gudmar Thorleifsson²⁰, Thomas W. Winkler³⁰, Michael E. Goddard^{33,34}, Ken Sin³⁵, Cameron Palmer^{9,10}, Tsegaselassie Workalemahu²², Yuri S. Aulchenko^{2,4}, Åsa Johansson^{35,36}, M. Carola Zillikens³, Mary F. Feitosa³⁷, Tõnu Esko^{38,39,40}, Toby Johnson^{41,42,43,44}, Shamika Ketkar³⁷, Peter Kraft^{45,46}, Massimo Mangino¹⁸, Inga Prokopenko^{13,47}, Devin Absher⁴⁸, Eva Albrecht³¹, Florian Ernst⁴⁹, Nicole L. Glazer⁵⁰, Caroline Hayward⁵¹, Jouke-Jan Hottenga⁵², Kevin B. Jacobs⁵³, Joshua W. Knowles⁵⁴, Zoltán Kutalik^{41,42}, Keri L. Monda⁵⁵, Ozren Polasek^{56,57}, Michael Preuss⁵⁸, Nigel W. Rayner^{13,47}, Neil R. Robertson^{13,47}, Valgerdur Steinthorsdottir²⁰, Jonathan P. Tyrer⁵⁹, Benjamin F. Voight^{11,14,15}, Fredrik Wiklund⁶⁰, Jianfeng Xu⁶¹, Jing Hua Zhao³², Dale R. Nyholt⁶², Niina Pellikka^{63,64}, Markus Perola^{63,64}, John R. B. Perry¹, Ida Surakka^{63,64}, Mari-Liis Tammesoo³⁸, Elizabeth L. Altmaier^{65,10}, Najaf Amin², Thor Axelund^{24,25}, Tushar Bhangale⁶⁵, Gabrielle Boucher⁶, Daniel I. Chasman^{66,67}, Constance Chen⁶⁸, Lachlan Coin⁶⁹, Matthew N. Cooper⁷⁰, Anna L. Dixon⁷¹, Quince Gibson⁷², Eliin Grundberg^{17,26,27}, Ke Hao⁷³, M. Juhani Junttila⁷⁴, Lee M. Kaplan^{16,67,75}, Johannes Kettunen^{63,64}, Inke R. König⁵⁸, Tony Kwan^{26,27}, Robert W. Lawrence⁷⁰, Douglas F. Levinson⁷⁶, Mattias Lorentzon⁷⁷, Barbara McKnight⁷⁸, Andrew P. Morris⁵³, Martina Müller^{17,79,80}, Julius Suh Ngwa⁸¹, Shaun Purcell^{14,82,83}, Suzanne Rafelt⁸⁴, Rany M. Salem^{9,10}, Erika Salvi^{85,86}, Serena Sanna⁸⁷, Jianxin Shi⁷, Ulla Sovio⁶⁹, John R. Thompson^{88,89}, Michael C. Turchin^{9,10}, Liesbeth Vandendput⁷⁷, Dominique J. Verlaan^{26,27}, Veronique Vitart⁵¹, Charles C. White⁸¹, Andreas Ziegler⁹⁰, Peter

Almgren⁹¹, Anthony J. Balmforth⁹², Harry Campbell⁹³, Lorena Citterio⁹⁴, Alessandro De Grandi⁹⁵, Anna Dominiczak⁹⁶, Jubao Duan⁹⁷, Paul Elliott⁹⁸, Roberto Elosua⁹⁹, Johan G. Eriksson^{100,101,102,103}, Nelson B. Freimer¹⁰⁴, Eco J. C. Geus⁵², Nicola Glorioso¹⁰⁵, Shen Haigui⁷², Anna-Liisa Hartikainen¹⁰⁶, Aki S. Havulinna¹⁰⁷, Andrew A. Hicks⁹⁵, Jennie Hui^{70,108,109}, Wilmar Igl³⁵, Thomas Illig³¹, Antti Jula¹¹⁰, Eero Kajantie¹⁰⁰, Tuomas O. Kilpeläinen³², Markku Koivranen¹¹¹, Ivana Kolcic⁵⁶, Seppo Koskinen¹⁰⁷, Peter Kovacs¹¹², Jaana Laitinen¹¹³, Jianjun Liu¹¹⁴, Marja-Liisa Lokki¹¹⁵, Ana Marusic¹¹⁶, Andrea Maschio⁸⁷, Thomas Meitinger^{117,118}, Antonella Mulas⁸⁷, Guillaume Paré¹¹⁹, Alex N. Parker¹²⁰, John F. Peden^{13,121}, Astrid Petersmann¹²², Irene Pichler⁹⁵, Kirsi H. Pietiläinen^{123,124}, Anneli Pouta^{106,125}, Martin Ridderstråle¹²⁶, Jerome I. Rotter¹²⁷, Jennifer G. Sambrook^{128,129}, Alan R. Sanders⁹⁷, Carsten Oliver Schmidt¹³⁰, Juha Sinisalo¹³¹, Jan H. Smit¹³², Heather M. Stringham⁵², G. Bragi Walters²⁰, Elisabeth Widen⁶³, Sarah H. Wild⁹³, Gonnelke Willemssen⁵², Laura Zagato⁹⁴, Lina Zgaga⁵⁶, Paavo Zitting¹³³, Helene Alavere³⁸, Martin Farrall^{13,121,134}, Wendy L. McArdle¹³⁵, Mari Nelis^{38,39,40}, Marjolein J. Peters^{3,4}, Samuli Ripatti^{63,64}, Joyce B. J. van Meurs^{2,3,4}, Katja K. Aben¹³⁶, Kristin G. Ardlie¹¹, Jacques S. Beckmann^{41,137}, John P. Beilby^{108,109,138}, Richard N. Bergman³⁹, Sven Bergmann^{41,42}, Francis S. Collins¹⁴⁰, Daniele Cusi⁸⁵, Martin den Heijer⁴¹, Gudny Eiriksdottir²⁴, Pablo V. Gejman⁹⁷, Alistair S. Hall⁹², Anders Hamsten¹⁴², Heikki V. Huikuri⁷⁴, Carlos Iribarren^{143,144}, Mika Kähönen¹⁴⁵, Jaakko Kaprio^{63,123,146}, Sekar Kathiresan^{11,14,147,148,149}, Lambertus Kiemeny^{136,150,151}, Thomas Kocher¹⁵², Lenore J. Launer¹⁵³, Terho Lehtimäki¹⁵⁴, Olle Melander¹²⁶, Tom H. Mosley Jr¹⁵⁵, Arthur W. Musk^{109,156}, Markku S. Nieminen¹³¹, Christopher J. O'Donnell^{148,157}, Claes Ohlsson⁷⁷, Ben Oostra¹⁵⁸, Lyle J. Palmer^{70,109}, Olli Raitakari¹⁵⁹, Paul M. Ridker^{66,67}, John D. Rioux^{5,6}, Aila Rissanen¹²⁴, Carlo Rivolta⁴¹, Heribert Schunkert¹⁶⁰, Alan R. Shuldiner^{72,161}, David S. Siscovick^{162,163}, Michael Stumvoll^{164,165}, Anke Tönjes^{164,166}, Jaakko Tuomilehto^{167,168,169}, Gert-Jan van Ommen¹⁷⁰, Jorma Viikari¹⁷¹, Andrew C. Heath¹⁷², Nicholas G. Martin¹⁷³, Grant W. Montgomery¹⁷⁴, Michael A. Province^{37,175}, Manfred Kayser¹⁷⁶, Alice M. Arnold^{78,177}, Larry D. Atwood²¹, Eric Boerwinkle¹⁷⁸, Stephen J. Chanock⁷, Panos Deloukas¹⁷⁹, Christian Gieger³¹, Henrik Grönberg⁶⁰, Per Hall⁶⁰, Andrew T. Hattersley¹⁸⁰, Christian Hengstenberg^{179,180}, Wolfgang Hoffman¹³⁰, G. Mark Lathrop¹⁸¹, Veikko Salomaa¹⁰⁷, Stefan Schreiber¹⁸², Manuela Uda¹⁸³, Dawn Waterworth¹⁸³, Alan F. Wright⁵¹, Themistocles L. Assimes⁵⁴, Inês Barroso^{17,184}, Albert Hofman^{2,4}, Karen L. Mohlke¹⁸⁵, Dorret I. Boomsma⁵², Mark J. Caulfield⁴⁴, L. Adrienne Cupples⁸¹, Jeanette Erdmann¹⁶⁰, Caroline S. Fox¹⁸⁶, Vilmondur Gudnason^{24,25}, Ulf Gyllenstein³⁵, Tamara B. Harris¹⁵³, Richard B. Hayes¹⁸⁷, Marjo-Riitta Jarvelin^{69,111,125,188}, Vincent Mooser¹⁸³, Patricia B. Munroe⁴⁴, Willem H. Ouweland^{17,128,129}, Brenda W. Penninx^{132,189,190}, Peter P. Pramstaller^{95,191,192}, Thomas Quertermous⁵⁴, Igor Rudan^{51,116}, Nilesh J. Samani^{84,88}, Timothy D. Spector¹⁸, Henry Völzke¹³⁰, Hugh Watkins on behalf of the Procardis Consortium^{13,121}, James F. Wilson⁹³, Leif C. Groop⁹¹, Talin Haritunians¹²⁷, Frank B. Hu^{22,23,45}, Robert C. Kaplan¹⁹³, Andres Metspalu^{38,39,40}, Kari E. North^{55,194}, David Schlessinger¹⁹⁵, Nicholas J. Wareham³², David J. Hunter^{22,23,45}, Jeffrey R. O'Connell⁷², David P. Strachan¹⁹⁶, H.-Erich Wichmann^{31,80,197}, Ingrid B. Borecki^{37,175}, Cornelia M. van Duijn²⁴, Eric E. Schadt^{198,199}, Unnur Thorsteinsdottir^{20,200}, Leena Peltonen^{17,63,64,82,201}, André G. Uitterlinden^{2,3,4}, Peter M. Visscher¹⁹, Nilanjana Chatterjee⁷, Ruth J. F. Loos³², Michael Boehnke⁸, Mark I. McCarthy^{13,47,202}, Erik Ingelsson⁶⁰, Cecilia M. Lindgren^{13,47}, Gonçalo R. Abecasis^{8*}, Kari Stefansson^{20,200*}, Timothy M. Frayling^{1*}, Joel N. Hirschhorn^{9,10,203*}

*These authors contributed equally to this work.

¹Genetics of Complex Traits, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter EX1 2LU, UK. ²Department of Epidemiology, Erasmus Medical Centre, 3015 GE Rotterdam, The Netherlands. ³Department of Internal Medicine, Erasmus Medical Centre, 3015 GE Rotterdam, The Netherlands. ⁴Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), 2300 RC Leiden, The Netherlands. ⁵Montreal Heart Institute, Montréal, Québec H1T 1C8, Canada. ⁶Department of Medicine, Université de Montréal, Montréal, Québec H3T 1J4, Canada. ⁷Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA. ⁸Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan 48109, USA. ⁹Divisions of Genetics and Endocrinology and Program in Genomics, Children's Hospital, Boston, Massachusetts 02115, USA. ¹⁰Metabolism Initiative and Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA. ¹¹Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA. ¹²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115 USA. ¹³Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK. ¹⁴Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ¹⁵Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ¹⁶Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ¹⁷Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK. ¹⁸Department of Twin Research and Genetic Epidemiology, King's College London, Lambeth Palace Road, London SE1 7EH, UK. ¹⁹Queensland Statistical Genetics Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia. ²⁰deCODE Genetics, 101 Reykjavik, Iceland. ²¹Department of Neurology, Boston University School of Medicine, Boston, Massachusetts 02118, USA. ²²Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ²³Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115 USA. ²⁴Icelandic Heart Association, Kopavogur, Iceland. ²⁵University of Iceland, 101 Reykjavik, Iceland. ²⁶McGill University and Genome Québec Innovation Centre, Montréal, Québec H3A 1A4, Canada. ²⁷Department of Human Genetics, McGill University Health Centre, McGill University, Montréal, Québec H3G 1A4, Canada. ²⁸Department of Medical Genetics, McGill University Health Centre, McGill University, Montréal, Québec

H3G 1A4, Canada. ²⁹Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Cambridge, Massachusetts 02138, USA. ³⁰Regensburg University Medical Center, Department of Epidemiology and Preventive Medicine, 93053 Regensburg, Germany. ³¹Institute of Epidemiology, Helmholtz Zentrum München – German Research Center for Environmental Health, 85764 Neuherberg, Germany. ³²MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. ³³Faculty of Land and Environment, University of Melbourne, Parkville 3010, Australia. ³⁴Department of Primary Industries, Bundoora, Victoria 3086, Australia. ³⁵Department of Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, SE-75185 Uppsala, Sweden. ³⁶Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), N-7489 Trondheim, Norway. ³⁷Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA. ³⁸Estonian Genome Center, University of Tartu, Tartu 50410, Estonia. ³⁹Estonian Biocenter, Tartu 51010, Estonia. ⁴⁰Institute of Molecular and Cell Biology, University of Tartu, Tartu 51010, Estonia. ⁴¹Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland. ⁴²Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland. ⁴³Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK. ⁴⁴Clinical Pharmacology and Barts and The London Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK. ⁴⁵Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ⁴⁶Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ⁴⁷Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK. ⁴⁸Hudson Alpha Institute for Biotechnology, Huntsville, Alabama 35806, USA. ⁴⁹Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany. ⁵⁰Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, Washington 98101, USA. ⁵¹MRC Human Genetics Unit, Institute for Genetics and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK. ⁵²Department of Biological Psychology, VU University Amsterdam, 1081 BT Amsterdam, The Netherlands. ⁵³Core Genotyping Facility, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland 21702, USA. ⁵⁴Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. ⁵⁵Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, USA. ⁵⁶Andrija Stampar School of Public Health, Medical School, University of Zagreb, 10000 Zagreb, Croatia. ⁵⁷Gen-Info Ltd, 10000 Zagreb, Croatia. ⁵⁸Universität zu Lübeck, Institut für Medizinische Biometrie und Statistik, 23562 Lübeck, Germany. ⁵⁹Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. ⁶⁰Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden. ⁶¹Center for Human Genomics, Wake Forest University, Winston-Salem, North Carolina 27157, USA. ⁶²Neurogenetics Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia. ⁶³Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014, Helsinki, Finland. ⁶⁴National Institute for Health and Welfare, Department of Chronic Disease Prevention, Unit of Public Health Genomics, FIN-00014 Helsinki, Finland. ⁶⁵Department of Genome Sciences, University of Washington, Seattle, 98195 Washington, USA. ⁶⁶Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA. ⁶⁷Harvard Medical School, Boston, Massachusetts 02115, USA. ⁶⁸Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA. ⁶⁹Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London W2 1PG, UK. ⁷⁰Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Crawley, Western Australia 6009, Australia. ⁷¹Royal National Hospital for Rheumatic Diseases and University of Bath, Bath BA1 1RL, UK. ⁷²Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. ⁷³Genetics Department, Rosetta Inpharmatics, a Wholly Owned Subsidiary of Merck & Co Inc., Seattle, Washington 98109, USA. ⁷⁴Department of Internal Medicine, University of Oulu, 90014 Oulu, Finland. ⁷⁵MGH Weight Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ⁷⁶Stanford University School of Medicine, Stanford, California 93405, USA. ⁷⁷Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden. ⁷⁸Departments of Biostatistics, University of Washington, Seattle, Washington 98195, USA. ⁷⁹Ludwig-Maximilians-Universität, Department of Medicine I, University Hospital Grosshadern, 81377 Munich, Germany. ⁸⁰Ludwig-Maximilians-Universität, Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, 81377 Munich, Germany. ⁸¹Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA. ⁸²The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA. ⁸³Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115, USA. ⁸⁴Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK. ⁸⁵University of Milan, Department of Medicine, Surgery and Dentistry, 20139 Milan, Italy. ⁸⁶KOS Genetic Srl, 20123 Milan, Italy. ⁸⁷Istituto di Neurogenetica e Neurofarmacologia del CNR, Monserrato, 09042 Cagliari, Italy. ⁸⁸Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester LE3 9QP, UK. ⁸⁹Department of Health Sciences, University of Leicester, University Road, Leicester LE1 7RH, UK. ⁹⁰Universität zu Lübeck, Institut für Medizinische Biometrie und Statistik, 23562 Lübeck, Germany. ⁹¹Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden. ⁹²Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, UK. ⁹³Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, Scotland, UK. ⁹⁴University Vita-Salute San Raffaele, Division of Nephrology and Dialysis, 20132 Milan, Italy. ⁹⁵Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Bolzano/Bozen, 39100, Italy. Affiliated Institute of the University of Lübeck, Lübeck, Germany. ⁹⁶British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK. ⁹⁷Northshore University Healthsystem,

Evanson, Illinois 60201, USA. ⁹⁸Cardiovascular Epidemiology and Genetics, Institut Municipal D'investigacio Medica and CIBER Epidemiologia y Salud Pública, Barcelona, Spain. ⁹⁹Department of General Practice and Primary Health Care, University of Helsinki, 00014, Helsinki, Finland. ¹⁰⁰National Institute for Health and Welfare, 00271 Helsinki, Finland. ¹⁰¹Helsinki University Central Hospital, Unit of General Practice, 00280 Helsinki, Finland. ¹⁰²Folkhalsan Research Centre, 00250 Helsinki, Finland. ¹⁰³Vasa Central Hospital, 65130 Vasa, Finland. ¹⁰⁴Center for Neurobehavioral Genetics, University of California, Los Angeles, California 90095, USA. ¹⁰⁵Hypertension and Cardiovascular Prevention Center, University of Sassari, 07100 Sassari, Italy. ¹⁰⁶Department of Clinical Sciences/Obstetrics and Gynecology, University of Oulu, 90014 Oulu, Finland. ¹⁰⁷National Institute for Health and Welfare, Department of Chronic Disease Prevention, Chronic Disease Epidemiology and Prevention Unit, 00014, Helsinki, Finland. ¹⁰⁸PathWest Laboratory of Western Australia, Department of Molecular Genetics, J Block, QEII Medical Centre, Nedlands, Western Australia 6009, Australia. ¹⁰⁹Busseleton Population Medical Research Foundation Inc., Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia. ¹¹⁰National Institute for Health and Welfare, Department of Chronic Disease Prevention, Population Studies Unit, 20720 Turku, Finland. ¹¹¹Institute of Health Sciences, University of Oulu, 90014 Oulu, Finland. ¹¹²Interdisciplinary Centre for Clinical Research, University of Leipzig, 04103 Leipzig, Germany. ¹¹³Finnish Institute of Occupational Health, 90220 Oulu, Finland. ¹¹⁴Human Genetics, Genome Institute of Singapore, Singapore 138672, Singapore. ¹¹⁵Transplantation Laboratory, Haartman Institute, University of Helsinki, 00014, Helsinki, Finland. ¹¹⁶Croatian Centre for Global Health, School of Medicine, University of Split, Split 21000, Croatia. ¹¹⁷Institute of Human Genetics, Klinikum rechts der Isar der Technischen Universität München, 81675 Munich, Germany. ¹¹⁸Institute of Human Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, 85764 Neuherberg, Germany. ¹¹⁹Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8N 3Z5, Canada. ¹²⁰Angen, Cambridge, Massachusetts 02139, USA. ¹²¹Department of Cardiovascular Medicine, University of Oxford, Level 6 West Wing, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK. ¹²²Institut für Klinische Chemie und Laboratoriumsmedizin, Universität Greifswald, 17475 Greifswald, Germany. ¹²³Finnish Twin Cohort Study, Department of Public Health, University of Helsinki, 00014, Helsinki, Finland. ¹²⁴Obesity Research unit, Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland. ¹²⁵National Institute for Health and Welfare, 90101 Oulu, Finland. ¹²⁶Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden. ¹²⁷Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. ¹²⁸Department of Haematology, University of Cambridge, Cambridge CB2 0PT, UK. ¹²⁹NHS Blood and Transplant, Cambridge Centre, Cambridge CB2 0PT, UK. ¹³⁰Institut für Community Medicine, 17489 Greifswald, Germany. ¹³¹Division of Cardiology, Cardiovascular Laboratory, Helsinki University Central Hospital, 00029 Helsinki, Finland. ¹³²Department of Psychiatry/EMGO Institute, VU University Medical Center, 1081 BT Amsterdam, The Netherlands. ¹³³Department of Physiatrics, Lapland Central Hospital, 96101 Rovaniemi, Finland. ¹³⁴Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford OX3 7BN, UK. ¹³⁵Avon Longitudinal Study of Parents and Children (ALSPAC) Laboratory, Department of Social Medicine, University of Bristol, Bristol BS8 2BN, UK. ¹³⁶Comprehensive Cancer Center East, 6501 BG Nijmegen, The Netherlands. ¹³⁷Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV) University Hospital, 1011 Lausanne, Switzerland. ¹³⁸School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, Western Australia 6009, Australia. ¹³⁹Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA. ¹⁴⁰National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. ¹⁴¹Department of Endocrinology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands. ¹⁴²Atherosclerosis Research Unit, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden. ¹⁴³Division of Research, Kaiser Permanente Northern California, Oakland, California 94612, USA. ¹⁴⁴Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94107, USA. ¹⁴⁵Department of Clinical Physiology, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland. ¹⁴⁶National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Unit for Child and Adolescent Mental Health, 00271 Helsinki, Finland. ¹⁴⁷Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ¹⁴⁸Framingham Heart Study of the National Heart, Lung, and Blood Institute and Boston University, Framingham, Massachusetts 01702, USA. ¹⁴⁹Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA. ¹⁵⁰Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands. ¹⁵¹Department of Urology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands. ¹⁵²Zentrum für Zahn-, Mund- und Kieferheilkunde, 17489 Greifswald, Germany. ¹⁵³Laboratory of Epidemiology, Demography, Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA. ¹⁵⁴Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland. ¹⁵⁵Department of Medicine, Division of Geriatrics, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA. ¹⁵⁶School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6009, Australia. ¹⁵⁷National, Lung, and Blood Institute, National Institutes of Health, Framingham, Massachusetts 01702, USA. ¹⁵⁸Department of Clinical Genetics, Erasmus Medical Centre, 3015 GE Rotterdam, The Netherlands. ¹⁵⁹Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku and the Department of Clinical Physiology, Turku University Hospital, 20520 Turku, Finland. ¹⁶⁰Universität zu Lübeck, Medizinische Klinik II, 23562 Lübeck, Germany. ¹⁶¹Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, Maryland 21201, USA. ¹⁶²Cardiovascular Health Research Unit, University of Washington, Seattle, Washington 98101, USA. ¹⁶³Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington 98195, USA. ¹⁶⁴Department of Medicine, University of Leipzig, 04103 Leipzig, Germany. ¹⁶⁵LIFE Study Centre, University of Leipzig, Leipzig, Germany. ¹⁶⁶Coordination Centre for Clinical Trials, University of Leipzig, Härtelstrasse 16-18, 04103 Leipzig, Germany. ¹⁶⁷National Institute for Health and Welfare, Diabetes Prevention Unit, 00271 Helsinki, Finland. ¹⁶⁸Hjelt Institute, Department of Public Health, University of Helsinki, 00014 Helsinki, Finland. ¹⁶⁹South Ostrobothnia Central Hospital, 60220 Seinajoki, Finland. ¹⁷⁰Department of Human Genetics and Center of Medical Systems Biology, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands. ¹⁷¹Department of Medicine, University of Turku and Turku University Hospital, 20520 Turku, Finland. ¹⁷²Department of Psychiatry and Midwest Alcoholism Research Center, Washington University School of Medicine, St Louis, Missouri 63108, USA. ¹⁷³Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia. ¹⁷⁴Molecular Epidemiology Laboratory, Queensland Institute of Medical Research, Queensland 4006, Australia. ¹⁷⁵Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri 63110, USA. ¹⁷⁶Department of Forensic Molecular Biology, Erasmus Medical Centre, 3015 GE Rotterdam, The Netherlands. ¹⁷⁷Collaborative Health Studies Coordinating Center, Seattle, Washington 98115, USA. ¹⁷⁸Human Genetics Center and Institute of Molecular Medicine and Division of Epidemiology, University of Texas Health Science Center, Houston, Texas 77030, USA. ¹⁷⁹Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, 93053 Regensburg, Germany. ¹⁸⁰Regensburg University Medical Center, Innere Medizin II, 93053 Regensburg, Germany. ¹⁸¹Centre National de Genotypage, Evry, Paris 91057, France. ¹⁸²Christian-Albrechts-University, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology and Department of Internal Medicine I, Schittenhelmstrasse 12, 24105 Kiel, Germany. ¹⁸³Genetics Division, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA. ¹⁸⁴University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK. ¹⁸⁵Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA. ¹⁸⁶Division of Intramural Research, National Heart, Lung, and Blood Institute, Framingham Heart Study, Framingham, Massachusetts 01702, USA. ¹⁸⁷New York University Medical Center, New York, New York 10016, USA. ¹⁸⁸Biocenter Oulu, University of Oulu, 90014 Oulu, Finland. ¹⁸⁹Department of Psychiatry, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands. ¹⁹⁰Department of Psychiatry, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands. ¹⁹¹Department of Neurology, General Central Hospital, Bolzano, Italy. ¹⁹²Department of Neurology, University of Lübeck, Lübeck, Germany. ¹⁹³Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York 10461, USA. ¹⁹⁴Carolina Center for Genome Sciences, School of Public Health, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27514, USA. ¹⁹⁵Laboratory of Genetics, National Institute on Aging, Baltimore, Maryland 21224, USA. ¹⁹⁶Division of Community Health Sciences, St George's, University of London, London SW17 0RE, UK. ¹⁹⁷Klinikum Grosshadern, 81377 Munich, Germany. ¹⁹⁸Pacific Biosciences, Menlo Park, California 94025, USA. ¹⁹⁹Sage Bionetworks, Seattle, Washington 98109, USA. ²⁰⁰Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland. ²⁰¹Department of Medical Genetics, University of Helsinki, 00014 Helsinki, Finland. ²⁰²NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LJ, UK. ²⁰³Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.